Abstract:Abstract Cancer cells usually generate and maintain higher levels of reactive oxygen species (ROS) compared to normal cells, in part because of their higher metabolic rate and defects in the electron transport chain. Because most tumor cells possess stronger antioxidative defense mechanisms to counterbalance excessive ROS, redox proteins such as thioredoxins (TRXs) and glutaredoxins (GRXs) are potential targets of anticancer therapy. We recently found that a novel redox protein called thioredoxin-like 2 (TXNL2) is required for embryonic stem cell functions and is consistently overexpressed in many different cancers. It has a TRX-homology domain and two GRX-homology domains, suggesting that it may have redox function. Using immunohistochemical and cDNA microarray analyses, we found that levels of TXNL2 were significantly higher (P = 0.00036) in human breast cancers than in normal breast tissues; levels also were higher in human breast cancer cell lines than in normal mammary epithelial cell lines. Knockdown of TXNL2 by shRNA in breast cancer cell lines induced a 5-fold increase of ROS levels and inhibited cell proliferation, survival, invasion, and the expression of genes critically involved in these cellular processes. Breast cancer stem-like cell populations and stem-like properties such as mammosphere formation were reduced by TXNL2 silencing and induced by TXNL2 overexpression. Surprisingly, TXNL2 depletion in normal mammary epithelial cells did not significantly affect ROS levels and cell survival. Xenograft models of orthotopic injection indicated that TXNL2 knockdown inhibited mammary tumor growth and metastasis to the lung. Cell signaling studies showed that TXNL2 knockdown inhibited GSH synthase (GSS) expression, and thereby decreased GSH levels and increased ROS levels; N-acetylcysteine (NAC), a GSH precursor, partially reversed these effects. In addition, TXNL2 knockdown suppressed NF-κB activity by inactivating IKK and p65 via glutathionylation, whereas TXNL2 overexpression markedly increased NF-κB activity. Blockade of NF-κB using its small-molecule inhibitors and IκB overexpression mimicked the effect of TXNL2 depletion. Our results suggest that TXNL2 is a potentially promising target for ROS-based anticancer therapies and is a key regulator of the NF-κB pathway. Because high cellular antioxidant capacity is well-known to impair cellular responses to chemotherapy and radiation therapy, our study may also open up a new avenue of maximize the efficacy of conventional anticancer therapies by targeting TXNL2. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1794.

NOX2-Derived Reactive Oxygen Species in Cancer

NOX2 Complex-Derived ROS As Immune Regulators.

The Role of NADPH Oxidase 2 in Normal and Malignant Hematopoiesis

The Association between NADPH Oxidase 2 (NOX2) and Drug Resistance in Cancer

Methylcholanthrene-Induced Sarcomas Develop Independently from NOX2-Derived ROS

NOX2 control over energy metabolism plays a role in acute myeloid leukaemia prognosis and survival

The Hematopoietic Oxidase NOX2 Regulates Self-Renewal of Leukemic Stem Cells

Tumoral NOX4 Recruits M2 Tumor-Associated Macrophages Via ROS/PI3K Signaling-Dependent Various Cytokine Production to Promote NSCLC Growth.

Reactive Oxygen Species and NRF2 Signaling, Friends or Foes in Cancer?

Carcinogenesis and Reactive Oxygen Species Signaling: Interaction of the NADPH Oxidase NOX1–5 and Superoxide Dismutase 1–3 Signal Transduction Pathways

Redox, cysteines, and kinases—A triad sustaining myeloid leukemia

Thioredoxin Activity Confers Resistance Against Oxidative Stress In Tumor-Infiltrating Nk Cells

Exosomal NOX1 promotes tumor-associated macrophage M2 polarization-mediated cancer progression by stimulating ROS production in cervical cancer: a preliminary study

Novel Role of Nox in Supporting Aerobic Glycolysis in Cancer Cells with Mitochondrial Dysfunction and As A Potential Target for Cancer Therapy

NADPH oxidase 1-dependent ROS is crucial for TLR4 signaling to promote tumor metastasis of non-small cell lung cancer

NOX2 Mediates Quiescent Handling of Dead Cell Remnants in Phagocytes

Structure, Activation, and Regulation of NOX2: At the Crossroad between the Innate Immunity and Oxidative Stress-Mediated Pathologies

The NADPH oxidase NOX2 is a marker of adverse prognosis involved in chemoresistance of Acute Myeloid Leukemias

NADPH oxidases: an overview from structure to innate immunity-associated pathologies

Txnl2 Is A Key Regulator Of Reactive Oxygen Species Levels And Nf-Kappa B Activity In Cancer Cells

NADPH Oxidase 2-Derived Reactive Oxygen Species Promote CD8+ T Cell Effector Function